|
Collaboration Arrangements (Details) (USD $)
|
12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | |||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
Dec. 31, 2011
GSK
|
Dec. 31, 2010
GSK
|
Dec. 31, 2009
GSK
|
Dec. 31, 2011
Astellas
|
Nov. 30, 2011
Class A common stock
GSK
|
Aug. 31, 2011
Class A common stock
GSK
|
Jul. 31, 2011
Class A common stock
GSK
|
May 31, 2011
Class A common stock
GSK
|
Feb. 28, 2011
Class A common stock
GSK
|
Dec. 31, 2011
Common Stock
|
Dec. 31, 2010
Common Stock
|
Dec. 31, 2002
Long-acting beta agonist (LABA) collaboration
Preferred stock
Series E
Glaxo Group Limited, an affiliate of GSK
|
Dec. 31, 2011
Long-acting beta agonist (LABA) collaboration
LAMA/LABA
Maximum
|
Dec. 31, 2011
Long-acting beta agonist (LABA) collaboration
LABA/RELOVAIR collaboration
Y
product
|
Dec. 31, 2010
Long-acting beta agonist (LABA) collaboration
LABA/RELOVAIR collaboration
|
Dec. 31, 2009
Long-acting beta agonist (LABA) collaboration
LABA/RELOVAIR collaboration
|
Dec. 31, 2011
Strategic alliance with GSK
|
Oct. 31, 2004
Strategic alliance with GSK
Class A common stock
GlaxoSmithKline LLC, an affiliate of GSK
|
May 31, 2004
Strategic alliance with GSK
Class A common stock
GlaxoSmithKline LLC, an affiliate of GSK
|
Nov. 30, 2010
Strategic alliance with GSK
Common Stock
Glaxo Group Limited, an affiliate of GSK
|
Dec. 31, 2009
Strategic alliance with GSK
LAMA
|
Dec. 31, 2011
Strategic alliance with GSK
LAMA
|
Dec. 31, 2011
Strategic alliance with GSK
MABA
product
|
Dec. 31, 2010
Strategic alliance with GSK
MABA
|
Dec. 31, 2009
Strategic alliance with GSK
MABA
|
Aug. 31, 2011
Strategic alliance with GSK
MABA containing '081
|
Dec. 31, 2011
Strategic alliance with GSK
MABA containing '081
|
Dec. 31, 2011
Strategic alliance with GSK
MABA containing '081 - single agent
|
Dec. 31, 2011
Strategic alliance with GSK
MABA containing '081 - single agent
Maximum
|
Dec. 31, 2011
Strategic alliance with GSK
MABA containing '081 - single agent
Minimum
|
Dec. 31, 2011
Strategic alliance with GSK
MABA containing '081 - combination product
|
Dec. 31, 2011
Strategic alliance with GSK
MABA containing additional MABA
product
|
Oct. 31, 2011
Strategic alliance with GSK
MABA containing additional MABA
|
Dec. 31, 2011
Strategic alliance with GSK
MABA containing additional MABA
Maximum
|
Dec. 31, 2011
Strategic alliance with GSK
MABA containing additional MABA - single agent
|
Dec. 31, 2011
Strategic alliance with GSK
MABA containing additional MABA - single agent
Maximum
|
Dec. 31, 2011
Strategic alliance with GSK
MABA containing additional MABA - single agent
Minimum
|
Dec. 31, 2011
Strategic alliance with GSK
MABA containing additional MABA - combination product
|
Dec. 31, 2011
Strategic alliance with GSK
Non-license specific
|
Dec. 31, 2010
Strategic alliance with GSK
Non-license specific
|
Dec. 31, 2009
Strategic alliance with GSK
Non-license specific
|
Dec. 31, 2011
License, Development and Commercialization Agreement With Astellas
|
Dec. 31, 2011
License, Development and Commercialization Agreement With Astellas
VIBATIV
|
Dec. 31, 2010
License, Development and Commercialization Agreement With Astellas
VIBATIV
|
Dec. 31, 2009
License, Development and Commercialization Agreement With Astellas
VIBATIV
|
Jan. 06, 2012
License, Development and Commercialization Agreement With Astellas
VIBATIV
Y
|
Dec. 31, 2011
License, Development and Commercialization Agreement With Astellas
VIBATIV
Astellas
|
Dec. 31, 2010
License, Development and Commercialization Agreement With Astellas
VIBATIV
Astellas
|
|
| Information related to collaboration arrangements | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Maximum obligation for milestone payments to GSK | $ 220,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Number of combination products | 2 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| If global regulatory authorities accept the applications for RELOVAIR, which the Company anticipates will be filed by GSK beginning in mid-2012, a portion of these potential milestone payments could be payable to GSK within the next two years. | 2 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Royalty rate for first level of annual global net sales (as a percent) | 15.00% | 20.00% | 10.00% | 15.00% | 10.00% | ||||||||||||||||||||||||||||||||||||||||||||||
| Royalty rate for combination products as a percentage of the rate applied to single products | 70.00% | 50.00% | |||||||||||||||||||||||||||||||||||||||||||||||||
| Royalty rate for sales above first level of annual global net sales (as a percent) | 5.00% | 7.50% | 10.00% | ||||||||||||||||||||||||||||||||||||||||||||||||
| Percentage of royalties receivable | 10.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Percentage of royalties payable to Astellas | 2.00% | 2.00% | |||||||||||||||||||||||||||||||||||||||||||||||||
| Annual global sales level used to determine royalty rate | 3,000,000,000 | 3,500,000,000 | 3,500,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Number of products which Company is obligated to use diligent efforts to discover after license of a program | 6 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Number of combination products to be developed and commercialized | 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Potential upfront license and milestone payments that Company could receive | 125,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Potential upfront license and milestone payments that Company could receive in respect of combination medicines | 250,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Milestone payments receivable | 129,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Entity's common stock information | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Common Stock Shares Purchased | 8,625,000 | 433,757 | 6,387,096 | 5,750,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| Aggregate Amounts | 93,478,000 | 86,000 | 6,900,000 | 108,900,000 | 129,400,000 | ||||||||||||||||||||||||||||||||||||||||||||||
| Purchase price of shares issued | 40,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock for cash in private placement to a related party (in shares) | 58,411 | 102,466 | 261,299 | 152,278 | 574,000 | 5,750,000 | |||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock for cash in private placement to a related party | 13,618,000 | 129,190,000 | 1,298,000 | 2,020,000 | 6,689,000 | 3,609,000 | 5,000 | 58,000 | |||||||||||||||||||||||||||||||||||||||||||
| Shares of Class A common stock converted into common stock | 9,401,499 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Number of shares of Class A stock convertible into one share of common stock | 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Number of shares of common stock into which one share of Class A stock can be converted | 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| GSK Upfront License Fees, Milestone Payments and Revenue | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Upfront License Fees | 10,000,000 | 41,000,000 | 5,000,000 | 6,000,000 | 1,000,000 | 20,000,000 | |||||||||||||||||||||||||||||||||||||||||||||
| Milestone Payments | 50,000,000 | 69,000,000 | 3,000,000 | 16,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| Total | 60,000,000 | 110,000,000 | 8,000,000 | 22,000,000 | 20,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||
| Milestone payment received | 3,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Term of royalty payment (in years) | 10 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| License, Development and Commercialization Agreement with Astellas | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Upfront license, milestone and other fees received | 191,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Net revenue recognized under the collaboration | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Amortization of deferred revenue | 9,658,000 | 9,826,000 | 15,073,000 | 4,718,000 | 5,081,000 | 5,081,000 | 4,240,000 | 3,082,000 | 2,007,000 | 3,014,000 | 936,000 | 1,858,000 | 2,738,000 | 2,738,000 | |||||||||||||||||||||||||||||||||||||
| Amortization of deferred revenue | 12,975,000 | 12,975,000 | 11,338,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Royalties from net sales of VIBATIV | 2,422,000 | 1,123,000 | 766,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Proceeds from VIBATIV delivered to Astellas | 24,512,000 | 24,223,000 | 24,374,000 | 1,171,000 | 2,058,000 | 1,171,000 | 2,058,000 | ||||||||||||||||||||||||||||||||||||||||||||
| Cost of VIBATIV delivered to Astellas | (1,177,000) | (938,000) | (1,629,000) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Cost of unrealizable VIBATIV inventory | (537,000) | (821,000) | (1,175,000) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Total net revenue | $ 14,854,000 | $ 14,397,000 | $ 9,300,000 | ||||||||||||||||||||||||||||||||||||||||||||||||